

## 20 ANNUAL 24 METING

**Don't Miss the ASTP Annual Meeting!** 

Washington, DC | December 4-5

www.ASTPAnnualMeeting.com





## Advancing the Science and Practice of Local Al Evaluation

Moderator:

Jordan Everson, PhD, MPP

Panelists:

Peter Embi, MD MS

**Corey Miller** 


Sara Murray, MD, MAS




#### The importance of local evaluation

Map: Price-Adjusted Physician Reimbursements per Enrollee, by HSA (2019) (Price, Age, Sex, and Race adjusted)

- Artificial and augmented intelligence are pattern recognizers
  - Make predictions based on simplifications of patterns including content generation
- Particularly likely to be wrong when patterns vary
- There is no such thing as a validated prediction model<sup>1</sup>
  - Patient populations vary
  - Measurements of predictors or outcomes vary
  - Populations and measurements change over time
- Local evaluation does not rely on generalizing from other sites<sup>2</sup>
  - Allows for pre-deployment testing where it will be used
  - Localization and monitoring to ensure reliable performance.









Adjusted Rate Medic.

\$1.035.46 \$6.122.47

#### HTI-1 Predictive DSI Source Attributes

#### 1) General Description and Outputs

- 1) Name and contact information for the intervention developer;
- 2) Funding source of the technical implementation for the intervention(s) development;
- 3) Description of value that the intervention produces as an output; and
- 4) Whether the intervention output is a prediction, classification, recommendation, evaluation, analysis, or other type of output.

- 5) Intended use of the intervention;
- 6) Intended patient population(s) for the intervention's use;

**Purpose** 

- 7) Intended user(s); and
- 8) Intended decision-making role for which the intervention was designed to be used/for.

#### 3 Cautioned Out-of-Scope Use

- 9) Description of tasks, situations, or populations where a user is cautioned against applying the intervention; and
- 10) Known risks, inappropriate settings, inappropriate uses, or known limitations.

#### 4) Development and Input Features

- 11) Exclusion and inclusion criteria that influenced the data set;
- 12) Use of variables in paragraph (b)(11)(iv)(A)(5)-(13) as input features;
- Description of demographic representativeness including, at a minimum, those used as input features in the intervention;
- 14) Description of relevance of training data to intended deployed setting;

#### 5 Process used to ensure fairness

- 15) Description of the approach the intervention developer has taken to ensure that the intervention's output is fair; and
- 16) Description of approaches to manage, reduce, or eliminate bias.

#### 6 External Validation Process

- 17) Description of the data source, clinical setting, or environment where an intervention's validity and fairness has been assessed, other than the source of training and testing data
- 18) Party that conducted the external testing;
- 19) Description of demographic representativeness of external data including, at a minimum, those used as input features in the intervention;
- 20) Description of external validation process.

#### 7) Quantitative Measures of Performance

- 21) Validity of intervention in test data derived from the same source as the initial training data;
- 22) Fairness of intervention in test data derived from the same source as the initial training data;
- 23) Validity of intervention in data external to or from a different source than the initial training data;
- 24) Fairness of intervention in data external to or from a different source than the initial training data;
- 25) References to evaluation of use of the intervention on outcomes, including, bibliographic citations or hyperlinks to evaluations of how well the intervention reduced morbidity, mortality, length of stay, or other outcomes;

#### 8 Ongoing Maintenance of Intervention

- 26) Description of process and frequency by which the intervention's validity is monitored over time;
- 27) Validity of intervention in local data;
- 28) Description of the process and frequency by which the intervention's fairness is monitored over time.
- 29) Fairness of intervention in local data; and

#### 9 Validation or Fairness Schedule

- 30) Description of process and frequency by which the intervention is updated; and
- 31) Description of frequency by which the intervention's performance is corrected when risks related to validity and fairness are identified.

#### Prevalence of Local Evaluation

# Proportion of hospitals that reported most or all models were evaluated using data from their hospital or health system (n=1,660).

Model Accuracy	1,009	61%
Model Bias	711	44%
Model Bias and Accuracy	709	44%

Note: 36 hospitals did not indicate whether they evaluated models for accuracy or bias and were excluded from analysis.

Paige Nong, Julia Adler-Milstein, Nate Apathy, A Jay Holmgren and Jordan Everson "Current Use And Evaluation Of Artificial Intelligence And Predictive Models In US Hospitals" Forthcoming, Health Affairs

Source: 2023 American Hospital Association Information Technology.




#### ASTP Decision Support Intervention Toolkit

- Recently awarded contract
- Assess needs for a set of tools to facilitate detection of bias in Al models
- Develop tools and share on ASTP web site
- Among other functions, tool will facilitate comparing local data to synthetic data to detect anomalies or potential unique biases in local data.



#### Local AI Evaluation at UCSF Health


- It is very difficult for health systems to know when AI is "trustworthy"
  - Limited regulation and standards for vendors
  - Healthcare delivery systems do not innately have Al assessment capabilities
- Early lessons in health Al use highlighted gaps across mission areas
  - Unreliable and/or biased vendor tools
  - Research tools deployed haphazardly without guardrails





### AI Oversight Across the AI Lifecycle

- Health Al Oversight Committee ensures all Al tools implemented in the health system are "trustworthy"
- Diverse, multidisciplinary committee with broad expertise
- Scope includes locally developed, vendor procured, and research tools





# UCSF IMPACC (Impact Monitoring Platform for AI in Clinical Care)

#### IMPACC = Al Monitoring Infrastructure + Robust Adjudication Process

- Unique partnership bridging health system and campus/academic expertise
- Generalizable monitoring infrastructure for all enterprise AI tools deployed at UCSF
  - Implementation and use, algorithmic vigilance, KPIs and outcomes

#### 3 Horizons of IMPACC AI Monitoring

Horizon 1: Basic Metrics

Horizon 2: Advanced Insights

Horizon 3: Open Research Questions





#### **Predictive Al**


#### Risk of Unplanned Readmission Adams, Kim Contribution Factor Value 19% Number of ED visits in the last six months Number of active inpatient medication 15 17% orders 16% ECG/EKG order Present in last 6 months 11% Imaging order Present in last 6 months 63 Age 8% Number of hospitalizations in last year high (1.1 mg/dL) 7% Latest creatinine 6% Charlson Comorbidity Index

Current length of stay


1 more factor not shown

2.238 days

#### **Generative Al**



### **Al Trust & Assurance Suite**





Implements major 3rdparty standards



Performance on local patient mix



Real-time, ongoing monitoring



Open-source template & schema



# Enabling Algorithmovigilance for Safe, Effective, & Equitable Health Al

#### Peter J. Embí, MD, MS, FACP, FACMI, FIAHSI

Professor of Biomedical Informatics and Medicine Chair, Department of Biomedical Informatics Endowed Directorship in Biomedical Informatics Co-Director, ADVANCE AI Center Senior Vice-President for Research & Innovation

ASTP/ONC Annual Meeting December 4, 2024





Al Discovery & Vigilance to Accelerate Innovation & Clinical Excellence



#### "Algorithmovigilance"



"The scientific methods and activities relating to the evaluation, monitoring, understanding, and prevention of adverse effects of algorithms in health care."



Akin to pharmacovigilance for monitoring drug effects



Increasingly important as AI/ML-derived algorithms are used





**Invited Commentary** | Health Informatics

#### Algorithmovigilance—Advancing Methods to Analyze and Monitor Artificial Intelligence–Driven Health Care for Effectiveness and Equity

Peter J. Embi, MD, MS

In recent years, there has been rapid growth and expansion in the use of machine learning and other artificial intelligence approaches applied to increasingly rich and accessible health data sets to develop algorithms that guide and support health care. As they make their way into practice, such algorithms have the potential to fundamentally transform how health care decisions are made and, therefore, how patients are diagnosed and treated. While such approaches hold great promise for enabling more precise, accurate, timely, and even fair decision-making when properly developed and applied, there is also growing evidence that systematic biases can lead to unintended and even severe consequences. Aftirroring disparities and inequities inherent in our society and health system, but also how algorithmic interventions are deployed.


Elsewhere in JAMA Network Open, Park and colleagues<sup>6</sup> present findings from a study evaluating different approaches to the debiasing of health care algorithms developed to predict postpartum depression (PPD) among a cohort of pregnant women with Medicaid coverage. The researchers, from IBM Research, leveraged the IBM MarketScan Medicaid Database, a deidentified, individual-level claim records data set with approximately 7 million Medicaid enrollees across multiple states, to derive their algorithms. They started by developing 2 sets of machine learning models trained to predict 2 outcomes: (1) diagnosis or treatment for PPD and (2) postpartum mental health service utilization. Their initial, risk-adjusted generalized linear models for each outcome demonstrated a notable difference in the cohort with binarized race, with White patients having twice the predicted likelihood of being diagnosed with PPD compared with Black patients and a significantly higher likelihood of utilizing mental health services. However, as the authors point out,


+ Related article

Author affiliations and article information are listed at the end of this article.

Embi PJ. JAMA Network Open. 2021;4(4):e214622.

## The Vanderbilt Algorithmovigilance Monitoring and Operations System (VAMOS)






## VAMOS DASHBOARD MOCK-UP


Show: All	Search:	Q		Show Alerts	Generate reports	•
-----------	---------	---	--	-------------	------------------	---

						F	PERFORM	<b>JANCE</b>			PR	OCESS		OUTCON	MES
Model Name	State	Criticality	Class	Next Review	Туре	Metric 1	Status	Metric 2	Status	Metric 1	Status	Metric 2	Status	Outcome	Status
Cornelius	Active	3	Clinical	<b>-4</b> d	BPA	Precision		Accuracy		Fire rate		Acceptance		Readmission	
Deterioration index	Inactive	1 A	Clinical	131 d	Story- board	Recall		Accuracy		Views				Clinical deterioration	
Post-partum hemorrhage	Maint.	1B	Clinical	68 d	Patient list	Brier Score		Precision		Appearance in lists				Uterine atony	
CLOT	Active	2	Clinical	<b>19</b> d	Order set	Precision		Accuracy		Views		Order acceptance		Hosp. VTE	
Others															



Select Metric	<b>\</b>
Accuracy	
AUC	
Bias	
Brier Score	
Drift	
Fire Rate	
O-to-E Ratio	
PPV	
Responsiveness	
Trigger Rate Stability	
Others	

#### Creating Local and Federated Algorithmovigilance (AV) Systems



# Thank You!



**Business Card** 



peter.embi@vumc.org



Questions or Comments?



@embimd.bsky.social



# Stay up-to-date on the agenda with the Annual Meeting app!

Download **ShoApp** in the App Store or Google Play.



## 20 ANNUAL 24 MEETING

X @HHS\_TechPolicy

Share your content on X and don't forget to use the hashtag #ASTP2024



#### **Today's Agenda**

#### December 4<sup>th</sup>

9:00 <sup>am</sup> - 11:30 <sup>am</sup>	Keynote Remarks from Micky Tripathi Morning Plenary: TEFCA - Year One in the Books and Looking to the Future
11:30 <sup>am</sup> – 1:00 <sup>pm</sup>	Lunch on your own
1:00 pm - 2:00 pm	Breakout Sessions I – View the ASTP Annual Meeting app for details
2:00 pm - 2:15 pm	Break
2:15 pm - 3:15 pm	Afternoon Plenary: Collaboration, Harmonization, and Standardization: How USCDI+ is Raising the Floor for Interoperable Data Use
3:15 pm - 3:45 pm	Break
3:45 pm - 5:00 pm	Breakout Sessions II – View the ASTP Annual Meeting app for details

#### Tomorrow's Agenda

December 5<sup>th</sup>

<ul> <li>Morning Plenaries:</li> <li>What the GPT? Does Al Have a Place in Health Care Delivery?</li> <li>Meeting the Mission with Al: How HHS is Using Al to Advance Health and Human Services</li> </ul>
Lunch on your own
Breakout Sessions III – View the ASTP Annual Meeting app for details
Break
Breakout Sessions IV – View the ASTP Annual Meeting app for details

#### **Today's Agenda**

December 5<sup>th</sup>

9:25 <sup>am</sup> – 11:30 <sup>am</sup>	<ul> <li>Morning Plenaries:</li> <li>What the GPT? Does AI Have a Place in Health Care Delivery?</li> <li>Meeting the Mission with AI: How HHS is Using AI to Advance Health and Human Services</li> </ul>
11:30 <sup>am</sup> – 1:00 <sup>pm</sup>	Lunch on your own
1:00 pm - 2:00 pm	Breakout Sessions III – View the ASTP Annual Meeting app for details
2:00 pm - 2:15 pm	Break
2:15 pm - 3:15 pm	Breakout Sessions IV – View the ASTP Annual Meeting app for details